| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$9 |
COMMENCEMENT OF RIGHTS TRADING
|
7 May 2025 8:52AM |
$0.005 |
$0.004 |
fallen by
30%
|
|
| Pengana Global Private Credit Trust (PCX) ORDINARY UNITS FULLY PAID |
Financials |
$226 |
Update - Notification of buy-back - PCX
|
7 May 2025 8:52AM |
$1.980 |
$1.960 |
fallen by
1.01%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$69 |
Update - Notification of buy-back - PCG
|
7 May 2025 8:51AM |
$0.815 |
$0.700 |
fallen by
14.11%
|
|
| Magellan Financial Group Limited (MFG) ORDINARY FULLY PAID |
Financials |
$1,882 |
Update - Notification of buy-back - MFG
|
7 May 2025 8:51AM |
$7.930 |
$10.260 |
risen by
29.38%
|
|
| Coda Minerals Ltd (COD) ORDINARY FULLY PAID |
Materials |
$47 |
Sydney RIU Conference Presentation
|
7 May 2025 8:51AM |
$0.076 |
$0.125 |
risen by
64.47%
|
|
| Pepper Money Limited (PPM) ORDINARY FULLY PAID |
Financials |
$833 |
Annual General Meeting - Presentation
|
7 May 2025 8:51AM |
$1.620 |
$1.855 |
risen by
14.51%
|
|
| Kalamazoo Resources Limited (KZR) ORDINARY FULLY PAID |
Materials |
$42 |
KZR Renews Victorian Focus on Gold-Antimony Exploration
|
7 May 2025 8:49AM |
$0.085 |
$0.135 |
risen by
59.76%
|
|
| Saunders International Limited (SND) ORDINARY FULLY PAID |
Industrials |
$122 |
Director Appointment/Resignation
|
7 May 2025 8:49AM |
$0.815 |
$0.875 |
risen by
7.36%
|
|
| Bastion Minerals Limited (BMO) ORDINARY FULLY PAID |
Materials |
- |
Quarterly Activities/Appendix 5B Cash Flow Report
|
7 May 2025 8:48AM |
$0.003 |
$0.051 |
risen by
1,600%
|
|
BMO - Price-sensitive ASX Announcement
Full Release
Key Points
- Exploration activities focused on Capote, Garin, and Cometa Projects in Chile
- Continued geological mapping, sampling, and drill preparation
- Corporate development and engagement with third parties for potential partnerships
- Review of new project opportunities in line with company strategy
- Detailed cash outflows for exploration and administration provided in Appendix 5B
- No mining production or development activities occurred during the quarter
- Compliance with ASX Listing Rule 5.3.1, 5.3.2, and 5.3.5 requirements
- Commitment to responsible exploration and stakeholder engagement reaffirmed
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amotiv Limited (AOV) ORDINARY FULLY PAID |
Consumer Discretionary |
$862 |
Update - Notification of buy-back - AOV
|
7 May 2025 8:44AM |
$7.900 |
$6.440 |
fallen by
18.48%
|
|
| Pengana Private Equity Trust (PE1) ORDINARY UNITS FULLY PAID |
Financials |
$397 |
Update - Notification of buy-back - PE1
|
7 May 2025 8:42AM |
$1.105 |
$1.485 |
risen by
34.39%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$288 |
Notification of cessation of securities - AMH
|
7 May 2025 8:42AM |
$1.065 |
$0.910 |
fallen by
14.55%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,324 |
2025 AGM - Proxy Summary
|
7 May 2025 8:42AM |
$5.010 |
$4.830 |
fallen by
3.59%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,324 |
2025 AGM - CEO's Address
|
7 May 2025 8:42AM |
$5.010 |
$4.830 |
fallen by
3.59%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$475 |
CUV recruits 200 patients in Phase III vitiligo trial CUV105
|
7 May 2025 8:41AM |
$11.300 |
$9.470 |
fallen by
16.19%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel Pharmaceuticals Limited reached the recruitment target of 200 patients for its Phase III trial (CUV105) on vitiligo.
- The CUV105 study is evaluating afamelanotide as a potential repigmentation therapy for vitiligo patients in North America.
- Vitiligo is a chronic skin disorder causing loss of pigmentation, affecting millions globally.
- The trial will assess both efficacy and safety endpoints of the treatment.
- Successful recruitment is a critical milestone enabling progress toward regulatory submission.
- There remains a significant unmet medical need for effective vitiligo treatments.
- Clinuvel sees this achievement as advancing its leadership in therapies for chronic and rare skin disorders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Santos Limited (STO) ORDINARY FULLY PAID |
Energy |
$26,047 |
2025 Santos Macquarie Conference Presentation
|
7 May 2025 8:41AM |
$5.880 |
$8.020 |
risen by
36.39%
|
|
| Pilot Energy Limited (PGY) ORDINARY FULLY PAID |
Energy |
$7 |
Notice of General Meeting/Proxy Form
|
7 May 2025 8:41AM |
$0.007 |
$0.057 |
risen by
714.29%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,324 |
2025 AGM - Chair's Address
|
7 May 2025 8:40AM |
$5.010 |
$4.830 |
fallen by
3.59%
|
|
| Singular Health Group Ltd (SHG) ORDINARY FULLY PAID |
Health Care |
$71 |
Exercise of Options and Cleansing Statement
|
7 May 2025 8:39AM |
$0.295 |
$0.225 |
fallen by
23.73%
|
|
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
Evaluation of Strategic Options Update
|
7 May 2025 8:38AM |
$0.100 |
$0.022 |
fallen by
78%
|
|
MDR - Price-sensitive ASX Announcement
Full Release
Key Points
- MedAdvisor Limited completed a formal strategic review of MedAdvisor US (MDR US).
- The company decided to retain MDR US within the group after evaluating all strategic options.
- MDR US demonstrated strong business performance and strategic fit with MedAdvisor’s long-term objectives.
- The Board highlighted improved operational results and growth prospects for the subsidiary.
- No sale or divestment will proceed for MDR US at this time.
- Leadership and management of MDR US received positive acknowledgment for delivering results.
- The company will focus on organic growth, operational improvements, and maximizing shareholder value.
- The Board thanked stakeholders for their support and reaffirmed commitment to the current strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| OD6 Metals Limited (OD6) ORDINARY FULLY PAID |
Materials |
$22 |
High-Grade Copper Massive Sulphides at Gulf Creek
|
7 May 2025 8:38AM |
$0.037 |
$0.087 |
risen by
135.14%
|
|
OD6 - Price-sensitive ASX Announcement
Full Release
Key Points
- OD6 Metals Limited discovered high-grade copper massive sulphides at Gulf Creek, NSW.
- Initial drilling program included six reverse circulation holes.
- Significant copper mineralisation intersected, with grades up to 19% Cu.
- Copper mineralisation is associated with silver and gold.
- Presence of massive and semi-massive sulphides confirmed.
- Results validate historical copper production and geological models.
- Further exploration work planned, including geophysical surveys and follow-up drilling.
- Exploration results support potential for resource growth at Gulf Creek.
- Announcement details exploration strategy and key technical findings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Franklin Australian Absolute Return Bond Fund (Managed Fund) (FRAR) |
Financials |
$718 |
Applications, Redemptions, Units on Issue and OTC 30.4.2025
|
7 May 2025 8:37AM |
$1.025 |
$1.040 |
risen by
1.46%
|
|
| Franklin Global Growth Fund (Managed Fund) (FRGG) |
Financials |
$205 |
Applications, Redemptions, Units on Issue and OTC 30.4.2025
|
7 May 2025 8:37AM |
$2.310 |
$1.710 |
fallen by
25.97%
|
|
| CI Resources Limited (CII) ORDINARY FULLY PAID |
Materials |
$149 |
Applications, Redemptions, Units on Issue and OTC 30.4.2025
|
7 May 2025 8:37AM |
$1.285 |
$1.285 |
fallen by
0%
|
|
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$631 |
Macquarie Australia Conference Presentation
|
7 May 2025 8:37AM |
$3.540 |
$1.520 |
fallen by
57.06%
|
|
BOE - Price-sensitive ASX Announcement
Full Release
Key Points
- Boss Energy Ltd presented at the Macquarie Australia Conference in May 2024.
- The company is focused on the development and operation of the Honeymoon Uranium Project located in South Australia.
- Honeymoon is one of only four uranium mines in Australia and recently re-commenced production.
- Boss Energy emphasizes its strong financial position with no debt and significant cash reserves.
- The company aims to become a leading global uranium producer and supplier amid growing demand for nuclear energy.
- Significant investment has been made in upgrading the Honeymoon plant and expanding its capacity.
- Boss highlights growing global interest and demand for uranium due to geopolitical supply risks and the energy transition push.
- Macquarie Australia Conference was used as a platform to update investors on operational progress and future plans.
- The company is committed to ESG principles, with a focus on safety, environmental responsibility, and community engagement.
- Boss Energy’s strategy involves targeting further resource exploration and production ramp-up to meet market demands.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.